US preparing 100% pharmaceutical tariffs- FT

The Trump administration is preparing to impose 100% tariffs on certain branded and patented pharmaceuticals, to be announced as soon as Thursday and applied to firms that have not struck deals with the White House. Tariffs will be capped based on imports from countries that reached agreements; Pfizer, AstraZeneca and Novo Nordisk are among companies that have signed deals. The move is aimed at forcing onshore investment and manufacturing and poses downside risk to affected drugmakers and pharma supply chains if implemented.

Analysis

A policy move that ties market access to on‑shore investment functionally turns trade policy into a corporate governance / capex filter: firms with existing U.S. manufacturing, long-term CDM (contract development & manufacturing) relationships, or pliable supply chains get an asymmetric premium in sentiment and valuation over peers. Expect differential re‑rating within 2–12 months — large caps with diversified, local production can trade through the headline risk while small/mid caps that rely on offshore finished‑product exports will face margin compression and increased working capital needs.

Second‑order flows will hit the supply chain: US domestic CMOs and precision equipment vendors see order book acceleration; conversely, commodity contract manufacturers in low‑cost jurisdictions attract rerouting and arbitrage (routing through treaty/exception countries to preserve market access). Patent‑heavy biologics and complex sterile injectables are the hardest to migrate quickly, creating a two‑tier survivability curve across drug types that will be visible in manufacturing CAPEX announcements over the next 6–18 months.

Tail risks and catalysts are highly idiosyncratic and time‑phased: headline volatility around official announcements (days) will be large, litigation/WTO challenges play out over quarters, and actual on‑shore capex takes years. A quick reversal is possible if enforcement is watered down or if major trade partners secure blanket exemptions — monitor bilateral deal cadence and MoUs as high‑probability inflection points.

The policy also raises cross‑sector optionality: industrials and domestic tech hardware that supply pharma manufacturing will pick up incremental demand, making semiconductor/AI hardware stocks a tactical hedge against pharma export disruption. Positioning should therefore be a mix of protected longs in deal‑insulated pharma plus targeted long exposure to domestic manufacturing beneficiaries, hedged with put spreads on export‑exposed small caps.

Key Decisions for Investors

• Initiate a relative‑value pair: Long PFE (size 1.5% NAV) and Long AZN (1.5% NAV) vs short XBI (0.75% NAV) — time horizon 3–9 months. Rationale: hedge into large, diversified manufacturers vs export‑exposed small cap biotech. Target 20–30% asymmetric upside on the longs if policy persists; cap losses to 8–10% by stop‑loss or rolling into calls.
• Buy NVO 6‑month call spread (buy 1x 6‑month ATM call, sell 1x 25% OTM call) — allocation 0.8% NAV. Rationale: capture rerating for a deal‑insulated leader with defined cost; max loss = premium, target 2.5x–3x return if tariffs remain enforced and earnings multiple expands.
• Tactical manufacturing hedge: Buy 3‑month put spread on XBI (10%–20% OTM) sized to cover 1% NAV of biotech exposure. Rationale: protects against a rapid de‑risking in small/mid pharma exporters around announcements; low cost, limited downside.
• Thematic hardware play: Long SMCI 6‑month call spread (buy ATM, sell 30% OTM) sized 1% NAV, entry on any >5% headline pullback. Rationale: benefits from incremental domestic spend on specialized compute and systems for on‑shore pharma manufacturing; target 1.5x–3x return, cut if policy rollback or sector fundamentals deteriorate.